Technology and Innovation

Disruptive Innovation and Transformation of the Drug Discovery and Development Enterprise

Evaluating the Clinical Utility of Genomic Variants Derived from Next-Generation Sequencing for Opportunistic Disease Screening and Risk Assessment: Evidence Gaps and Priorities

  The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...

Join Our Community

Sign up for NAM email updates